[PDF][PDF] Tackling COVID-19 with neutralizing monoclonal antibodies
Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
[HTML][HTML] COVID-19: breaking down a global health crisis
Abstract Coronavirus disease 2019 (COVID-19) is the second pandemic of the twenty-first
century, with over one-hundred million infections and over two million deaths to date. It is a …
century, with over one-hundred million infections and over two million deaths to date. It is a …
[HTML][HTML] Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform …
G Reis, EA dos Santos Moreira-Silva… - The Lancet Global …, 2022 - thelancet.com
Background Recent evidence indicates a potential therapeutic role of fluvoxamine for
COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we …
COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we …
Severe covid-19 pneumonia: pathogenesis and clinical management
AH Attaway, RG Scheraga, A Bhimraj, M Biehl… - bmj, 2021 - bmj.com
Severe covid-19 pneumonia has posed critical challenges for the research and medical
communities. Older age, male sex, and comorbidities increase the risk for severe disease …
communities. Older age, male sex, and comorbidities increase the risk for severe disease …
Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection
MJ Peluso, S Lu, AF Tang… - The Journal of …, 2021 - academic.oup.com
Background The biological processes associated with postacute sequelae of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are unknown. Methods …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are unknown. Methods …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
[HTML][HTML] ESCMID COVID-19 living guidelines: drug treatment and clinical management
M Bartoletti, O Azap, A Barac, L Bussini… - Clinical Microbiology …, 2022 - Elsevier
Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …
Hyperimmune immunoglobulin for people with COVID‐19
V Piechotta, C Iannizzi, I Monsef… - Cochrane Database …, 2023 - cochranelibrary.com
Background Hyperimmune immunoglobulin (hIVIG) contains polyclonal antibodies, which
can be prepared from large amounts of pooled convalescent plasma or prepared from …
can be prepared from large amounts of pooled convalescent plasma or prepared from …
[HTML][HTML] COVID-19: unmasking emerging SARS-CoV-2 variants, vaccines and therapeutic strategies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of
the coronavirus disease 2019 (COVID-19) pandemic, which has been a topic of major …
the coronavirus disease 2019 (COVID-19) pandemic, which has been a topic of major …
Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review
L Ghosn, R Assi, T Evrenoglou… - Cochrane database …, 2023 - cochranelibrary.com
Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …